慢性自发性荨麻疹活动度相关生物学指标的研究进展

doi:10.35541/cjd.20201158

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (6): 559-562.doi: 10.35541/cjd.20201158

慢性自发性荨麻疹活动度相关生物学指标的研究进展

焦晴晴¹ 张晓艳² 季江²

¹苏州大学附属第二医院皮肤性病科，苏州 215006；²苏州大学附属第一医院皮肤性病科，苏州 215004

收稿日期:2020-12-02 修回日期:2021-03-01 发布日期:2023-06-05
通讯作者: 季江 E-mail:jijiang@suda.edu.cn
基金资助:
国家自然科学基金（82073434）；江苏省卫生健康委医学科研项目（Z2020017）；民生科技-医疗卫生应用基础项目（SYS2020135）

Biological indicators related to disease activity of chronic spontaneous urticaria: an update

Jiao Qingqing¹, Zhang Xiaoyan², Ji Jiang²

¹Department of Dermatology and Venereology, The Second Affiliated Hospital of Soochow University, Suzhou 215006, China; ²Department of Dermatology and Venereology, The First Affiliated Hospital of Soochow University, Suzhou 215004, China

Received:2020-12-02 Revised:2021-03-01 Published:2023-06-05
Contact: Ji Jiang E-mail:jijiang@suda.edu.cn
Supported by:
National Natural Science Foundation of China （82073434）; Medical Research Project of Jiangsu Provincial Health Commission （Z2020017）; People′s Livelihood Science and Technology-Medical and Health Application Foundation （SYS2020135）

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹是一种反复发作的全身炎症性疾病。目前临床上能有效反映慢性自发性荨麻疹疾病活动度的生物学指标不多，且部分指标也没有得到广泛应用。若能找到一个或多个灵敏且便于检查的指标，将有助于对此病的诊断、治疗和疗效预测。本文综合评估目前慢性自发性荨麻疹疾病活动度相关指标的临床应用情况，为临床和相关科研工作提供参考。

关键词: 荨麻疹, 慢性自发性荨麻疹, 疾病活动度, 生物学检测指标

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is a recurrent systemic inflammatory disease. At present, there are few biological indicators that can effectively reflect CSU activity in clinical practice, and some indicators have not been widely used. To identify sensitive and easy-to-check indicators may be helpful for the diagnosis and treatment of as well as prediction of therapeutic efficacy in CSU. This review comprehensively summarizes current clinical application of indicators related to CSU activity, in order to provide a reference for clinical practice and related scientific research.

Key words: Urticaria, Chronic spontaneous urticaria, Disease activity, Biological indicators

焦晴晴张晓艳季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2023,56(6):559-562. doi:10.35541/cjd.20201158

Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update[J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562.doi:10.35541/cjd.20201158

参考文献 34

［1］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［2］	Saini SS, Kaplan AP. Chronic spontaneous urticaria: the Devil′s itch［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1097⁃1106. doi: 10.1016/j.jaip.2018.04.013.
［3］	Marsland AM. Autoimmunity and complement in the pathogenesis of chronic urticaria［J］. Curr Allergy Asthma Rep, 2006,6（4）:265⁃269. doi: 10.1007/s11882⁃006⁃0058⁃8.
［4］	Pałgan K, Bartuzi Z. Platelet activating factor in allergies［J］. Int J Immunopathol Pharmacol, 2015,28（4）:584⁃589. doi: 10.1177/0394632015600598.
［5］	Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system ［J］. AllergolInt, 2018,67（2）:191⁃194. doi: 10.1016/j.alit.2017.09.003.
［6］	Jain S. Pathogenesis of chronic urticaria: an overview［J］. Dermatol Res Pract, 2014,2014:674709. doi: 10.1155/2014/674709.
［7］	Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects［J］. Allergy, 2014,69（6）:683⁃691. doi: 10.1111/all.12389.
［8］	Ulambayar B, Yang EM, Cha HY, et al. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study［J］. Clin Transl Allergy, 2019,9:33. doi: 10.1186/s13601⁃019⁃0275⁃6.
［9］	Vadas P, Perelman B, Liss G. Platelet⁃activating factor, histamine, and tryptase levels in human anaphylaxis［J］. J Allergy Clin Immunol, 2013,131（1）:144⁃149. doi: 10.1016/j.jaci.2012.08.016.
［10］	Aleem S, Masood Q, Hassan I. Correlation of mean platelet volume levels with severity of chronic urticaria［J］. Indian J Dermatol, 2014,59（6）:636. doi: 10.4103/0019⁃5154.143607.
［11］	Hide M, Suzuki T, Tanaka A, et al. Long⁃term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12⁃month, multicenter, open⁃label clinical trial［J］. J Dermatol Sci, 2019,94（3）:339⁃345. doi: 10.1016/j.jdermsci.2019.05.008.
［12］	Hong GU, Park BS, Park JW,et al. IgE production in CD40/CD40L cross⁃talk of B and mast cells and mediator release via TGase 2 in mouse allergic asthma［J］. Cell Signal, 2013,25（6）:1514⁃1525. doi: 10.1016/j.cellsig.2013.03.010.
［13］	Bae Y, Kang SH, Park JO, et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria［J］. Allergol Int, 2020,69（2）:304⁃306. doi: 10.1016/j.alit.2019.10.009.
［14］	Johnson ED, Schell JC, Rodgers GM. The D⁃dimer assay［J］. Am J Hematol, 2019,94（7）:833⁃839. doi: 10.1002/ajh.25482.
［15］	Vadasz Z, Toubi E. Hemostasis in allergy［J］. Semin Thromb Hemost, 2018,44（7）:669⁃675. doi: 10.1055/s⁃0038⁃1648232.
［16］	Triwongwaranat D, Kulthanan K, Chularojanamontri L, et al. Correlation between plasma D⁃dimer levels and the severity of patients with chronic urticaria［J］. Asia Pac Allergy, 2013,3（2）:100⁃105. doi: 10.5415/apallergy.2013.3.2.100.
［17］	Asero R. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?［J］. Eur Ann Allergy Clin Immunol, 2020,52（6）:268⁃270. doi: 10.23822/EurAnnACI.1764⁃1489.139.
［18］	de Montjoye L, Darrigade AS, Giménez⁃Arnau A, et al. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria［J］. Eur Ann Allergy Clin Immunol, 2021,53（2）:55⁃66. doi: 10.23822/EurAnnACI.1764⁃1489.132.
［19］	Varghese R, Rajappa M, Chandrashekar L, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria［J］. Ann Allergy Asthma Immunol, 2016,116（4）:344⁃348. doi: 10.1016/j.anai.2016.01. 016.
［20］	Trinh HK, Pham DL, Ban GY, et al. Altered systemic adipokines in patients with chronic urticaria［J］. Int Arch Allergy Immunol, 2016,171（2）:102⁃110. doi: 10.1159/000452626.
［21］	Zwicky P, Unger S, Becher B. Targeting interleukin⁃17 in chronic inflammatory disease: a clinical perspective［J］. J Exp Med, 2020,217（1）:e20191123. doi: 10.1084/jem.20191123.
［22］	Teng MW, Bowman EP, McElwee JJ, et al. IL⁃12 and IL⁃23 cytokines: from discovery to targeted therapies for immune⁃mediated inflammatory diseases［J］. Nat Med, 2015,21（7）:719⁃729. doi: 10.1038/nm.3895.
［23］	Sharma P, Sharma PK, Chitkara A, et al. To evaluate the role and relevance of cytokines IL⁃17, IL⁃18, IL⁃23 and TNF⁃α and their correlation with disease severity in chronic urticaria［J］. Indian Dermatol Online J, 2020,11（4）:594⁃597. doi: 10.4103/idoj.IDOJ_396_19.
［24］	Shoda T, Futamura K, Orihara K, et al. Recent advances in understanding the roles of vascular endothelial cells in allergic inflammation［J］. Allergol Int, 2016,65（1）:21⁃29. doi: 10.1016/j.alit.2015.08.001.
［25］	Zhang L, Qi R, Yang Y, et al. Serum miR⁃125a⁃5p and CCL17 upregulated in chronic spontaneous urticaria and correlated with treatment response［J］. Acta Derm Venereol, 2019,99（6）:571⁃578. doi: 10.2340/00015555⁃3149.
［26］	Metz M, Krull C, Maurer M. Histamine, TNF, C5a, IL⁃6, ⁃9, ⁃18, ⁃31, ⁃33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria［J］. J Dermatol Sci, 2013,70（3）:222⁃225. doi: 10.1016/j.jdermsci.2013.03.003.
［27］	Elieh Ali Komi D, Shafaghat F, Kovanen PT, et al. Mast cells and complement system: ancient interactions between components of innate immunity［J］. Allergy, 2020,75（11）:2818⁃2828. doi: 10.1111/all.14413.
［28］	Kasperska⁃Zajac A, Grzanka A, Machura E, et al. Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration［J］. J Inflamm （Lond）, 2013,10（1）:22. doi: 10. 1186/1476⁃9255⁃10⁃22.
［29］	Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium internationale allergologicum （CIA） update 2020［J］. Int Arch Allergy Immunol, 2020,181（5）:321⁃333. doi: 10.1159/000507 218.
［30］	Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty⁃five patients［J］. Allergol Int, 2018,67（1）:85⁃89. doi: 10.1016/j.alit.2017.05.003.
［31］	Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,140（6）:1749⁃1751. doi: 10.1016/j.jaci.2017.08.007.
［32］	Kessel A, Helou W, Bamberger E, et al, Elevated serum total IgE⁃⁃a potential marker for severe chronic urticaria［J］. Int Arch Allergy Immunol, 2010,153（3）:288⁃293. doi: 10.1159/000314370.
［33］	Chanprapaph K, Iamsumang W, Wattanakrai P, et al. Thyroid autoimmunity and autoimmunity in chronic spontaneous urticaria linked to disease severity, therapeutic response, and time to remission in patients with chronic spontaneous urticaria［J］. Biomed Res Int, 2018,2018:9856843. doi: 10.1155/ 2018/9856843.
［34］	Curto⁃Barredo L, Yelamos J, Gimeno R, et al. Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease［J］. Immun Inflamm Dis, 2016,4（4）:441⁃445. doi: 10.1002/iid3.125.

[1]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[2]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[3]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495.
[4]	陈奇权杨显杰王文稳梁高澎宋志强. 胆碱能性荨麻疹临床评估工具的开发及应用进展[J]. 中华皮肤科杂志, 2023, 56(6): 563-566.
[5]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[6]	张立明肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570.
[7]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.
[8]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[9]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[10]	王鑫刘丽娟李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530.
[11]	李丽俏彭聪陈翔李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511.
[12]	杨晓静陈雷刚王世宁吴远慧朱由瑾安国芝周向昭孟昭影. 慢性自发性荨麻疹患者血清白细胞介素9、血小板活化因子水平与总IgE、病情严重程度和病程的相关性研究[J]. 中华皮肤科杂志, 2023, 56(4): 337-341.
[13]	佟馨吴剑张立明高兴华连石张海萍朱威郭在培黎静宜李萌萌何黎农祥普雄明于世荣陈洪铎肖汀. 食物特异性IgG抗体与慢性自发性荨麻疹表型的相关性研究[J]. 中华皮肤科杂志, 2023, 56(2): 130-135.
[14]	于淼宋晓婷刘擘廖双璐栾婷婷赵作涛. 慢性自发性荨麻疹患者自体血清皮肤试验的免疫学机制及与临床特征和预后的关系[J]. 中华皮肤科杂志, 2023, 56(2): 184-187.
[15]	赵莹张晓艳陈璐苏玉华丁瑜洁冷红季江. 奥马珠单抗治疗难治性慢性自发性荨麻疹患者的疗效预测因子探索[J]. 中华皮肤科杂志, 2023, 56(1): 22-28.

慢性自发性荨麻疹活动度相关生物学指标的研究进展

Biological indicators related to disease activity of chronic spontaneous urticaria: an update

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

Metrics

本文评价

推荐阅读 10